Corporate Misconduct Accountability Project
Wells Fargo & Company · Class Action
Wells Fargo Allegedly Overcharged Employees Billions for Prescriptions
A class action lawsuit accuses Wells Fargo of breaching fiduciary duties under ERISA by allowing Express Scripts to charge employees up to 4,700% markups on generic prescription drugs, forcing workers to pay inflated premiums and copays while the bank failed to monitor or renegotiate.
CRITICAL SEVERITY
TL;DR
Wells Fargo employees filed a class action alleging the bank violated federal law by allowing its pharmacy benefits manager, Express Scripts, to overcharge the employee health plan by thousands of percent on generic drugs. Workers paid a multiple sclerosis drug that costs $648 at retail for nearly $10,000 through the plan. The lawsuit claims Wells Fargo failed its legal duty to monitor costs, negotiate fair prices, or consider alternatives, forcing over 200,000 employees to shoulder higher premiums, copays, and deductibles while Express Scripts pocketed excessive profits.
If your employer offers health insurance, you may be overpaying for prescriptions without knowing it.
$9,994
Price Wells Fargo plan paid for fingolimod vs. $648 retail
$8,775
Price plan paid for teriflunomide vs. $80-90 retail
4,700%
Maximum markup on imatinib above pharmacy acquisition cost
$25M
Administrative fees paid to Express Scripts in one year
$135.81
Average per-participant administrative fee vs. lower at comparable employers
$600M+
Annual employee contributions to Wells Fargo health plan
25%
Share of total plan costs employees pay through premiums
200,000+
Wells Fargo employees covered by the health plan
The Allegations: A Breakdown
Core Allegations
What they did · 8 points
| 01 | Wells Fargo allowed Express Scripts to charge the employee health plan $9,994.37 for a 90-day supply of fingolimod, a multiple sclerosis drug, while the same prescription costs $648 to $900 at Wegmans, Walmart, or Rite Aid without insurance. | high |
| 02 | The plan paid $8,775.91 for 90 tablets of teriflunomide, another MS medication, while Walmart and ShopRite offer the same prescription for $80 to $90 in cash. | high |
| 03 | Express Scripts marked up imatinib, a chemotherapy drug for leukemia, by as much as 4,700 percent above the average pharmacy acquisition cost. | high |
| 04 | Wells Fargo paid Express Scripts over $25 million in administrative fees in a single year, averaging $135.81 per participant, far exceeding fees paid by comparable employers for the same services. | high |
| 05 | The bank forced employees to fill specialty drug prescriptions exclusively at Accredo, a pharmacy owned by Express Scripts, where markups were often thousands of percent higher than retail pharmacies. | high |
| 06 | Wells Fargo based generic drug pricing on Average Wholesale Price, a notoriously inflated and manipulable benchmark, instead of the transparent National Average Drug Acquisition Cost used by prudent plan sponsors. | medium |
| 07 | The bank failed to conduct competitive bidding, never considered pass-through pharmacy benefit managers that eliminate spread pricing, and did not audit Express Scripts claims to verify fair pricing. | high |
| 08 | Wells Fargo allowed Express Scripts to unilaterally classify drugs as specialty without objective clinical criteria, enabling the PBM to funnel prescriptions to its own high-markup pharmacy. | medium |
Regulatory Failures
How the system enabled this · 6 points
| 01 | ERISA requires plan fiduciaries to manage employee benefits with the highest standard of care known to law, but enforcement relies almost entirely on employees filing lawsuits after damage is done. | high |
| 02 | No federal law prohibits pharmacy benefit managers from using Average Wholesale Price, a pricing benchmark insiders joke stands for ‘Ain’t What’s Paid’ because it bears no relation to actual drug costs. | medium |
| 03 | The top three PBMs control over 75 percent of commercial prescriptions in an oligopoly with limited competition, allowing Express Scripts, CVS Caremark, and OptumRx to maintain opaque contracts and hidden rebates. | high |
| 04 | Employee benefit consultants and brokers often receive undisclosed commissions from PBMs, creating conflicts of interest where the consultant profits from steering employers to high-cost arrangements. | high |
| 05 | Express Scripts owns Accredo pharmacy, allowing the same corporate parent to control both the price negotiations and the dispensing, profiting from artificially inflated charges on both ends. | high |
| 06 | Employees cannot see what the plan actually pays for drugs, only their copay portion, making it nearly impossible to detect that the plan paid $10,000 for a prescription available for $800 at retail. | medium |
Profit Over People
Corporate greed in action · 6 points
| 01 | Wells Fargo holds significant bargaining power as a financial giant with over 200,000 employees, yet the bank failed to exercise that leverage to negotiate fair prescription drug prices for its workforce. | high |
| 02 | The bank allowed Express Scripts to retain spread pricing profits by charging the plan far more than the PBM paid pharmacies, pocketing the difference instead of passing savings to employees. | high |
| 03 | Express Scripts negotiated rebates with drug manufacturers but passed only a portion or none of those rebates to the Wells Fargo plan, keeping the financial benefit for itself. | high |
| 04 | Wells Fargo never requested proposals from pass-through PBMs like Navitus or SmithRx, which charge only transparent administrative fees and pass 100 percent of rebates and discounts to the plan. | medium |
| 05 | Numerous Fortune 500 companies recognized the savings from pass-through models or specialty drug carve-outs and switched away from traditional PBMs, but Wells Fargo did not follow suit despite the documented benefits. | medium |
| 06 | The lawsuit alleges Wells Fargo treated inflated prescription costs as just another cost of doing business, ultimately forcing employees to subsidize PBM profits through higher premiums and out-of-pocket expenses. | high |
Worker Exploitation
Who paid the price · 6 points
| 01 | Employees contributed over $600 million per year to the Wells Fargo health plan, with workers paying approximately 25 percent of total plan costs through paycheck deductions. | high |
| 02 | Every $100 million increase in plan costs due to PBM overcharges translated to $25 million in additional premium contributions extracted directly from employee paychecks. | high |
| 03 | Workers with chronic conditions like multiple sclerosis, HIV, or cancer faced especially punishing bills when Express Scripts set specialty drug prices exponentially higher than retail, forcing some to skip doses or cut pills to manage costs. | high |
| 04 | Higher out-of-pocket costs proved financially ruinous for employees on lower salary scales, with an extra $100 to $200 per month in premiums or copays forcing families to forgo essentials like healthy food or childcare. | high |
| 05 | Plan overspending on prescriptions drained resources that could have expanded coverage, lowered premiums, or increased wages, directly harming employees’ total compensation and financial security. | medium |
| 06 | Employees experienced job lock, fearing the loss of health coverage despite inflated costs, while older workers delayed retirement due to the financial burden of prescription drug expenses. | medium |
Corporate Accountability Failures
Who knew and when · 6 points
| 01 | Wells Fargo executives named in the lawsuit include Michael Branca and Mark Hickman, who served as plan administrators with legal responsibility to ensure the plan operated in employees’ best interests. | high |
| 02 | The bank failed to monitor Express Scripts performance, never audited whether the PBM charged fair prices, and did not investigate alternative arrangements despite red flags about inflated costs. | high |
| 03 | Wells Fargo allegedly allowed the overcharging to persist for years without opening the contract to competitive bidding or requesting proposals from cost-effective alternatives. | high |
| 04 | The lawsuit alleges prohibited transactions under ERISA, meaning Wells Fargo may have transferred plan assets to benefit parties with massive conflicts of interest rather than plan participants. | high |
| 05 | Plan fiduciaries did not steer participants to cost-friendly pharmacies, did not challenge how specialty designations were assigned, and remained either willfully blind or outright supportive of arrangements detrimental to the workforce. | medium |
| 06 | ERISA holds fiduciaries to the highest standard of care known to law, making Wells Fargo’s alleged failure to rein in inflated drug prices a potential betrayal of legal trust, not merely corporate laziness. | high |
Public Health and Safety
The medical consequences · 4 points
| 01 | Employees with serious medical conditions faced dangerously high copays and coinsurance on inflated prices, with coinsurance on a $10,000 prescription proving far more punishing than on an $800 prescription for the same drug. | high |
| 02 | Workers rationed or skipped doses of critical medications for multiple sclerosis, cancer, and HIV because the plan’s inflated specialty drug prices made prescriptions unaffordable even with insurance coverage. | high |
| 03 | The lawsuit documents how employees could not access lower-cost retail pharmacies for many prescriptions because Express Scripts forced them to use Accredo, eliminating patient choice and access to affordable alternatives. | medium |
| 04 | Inflated healthcare costs contributed to delayed medical treatment and foregone prescriptions, worsening health outcomes for employees who could not afford the copays on drugs marked up thousands of percent. | high |
Wealth Disparity
Making inequality worse · 5 points
| 01 | Wells Fargo’s alleged cost-shifting transferred billions in prescription drug expenses from corporate balance sheets onto workers, widening the wealth gap between executives and employees struggling with medical bills. | high |
| 02 | Lower-wage employees bore the same premium increases and inflated copays as higher-paid workers, making prescription overcharges regressive and disproportionately harmful to those least able to afford them. | high |
| 03 | The bank’s failure to control drug costs likely suppressed wage growth, as higher benefit expenses for the employer indirectly capped future salary increases for the workforce. | medium |
| 04 | Employees who spent hundreds of extra dollars monthly on premiums and prescriptions cut discretionary spending, harming local economies and reducing workers’ ability to save for retirement or emergencies. | medium |
| 05 | Corporate executives remained insulated from accountability while front-line workers faced financial ruin from medical expenses, exemplifying how neoliberal capitalism shifts liabilities from powerful institutions to vulnerable individuals. | high |
The Bottom Line
What this means · 6 points
| 01 | The lawsuit provides a detailed blueprint of how large corporations exploit regulatory loopholes, engage in opaque spread pricing, and pass costs to workers while pharmacy benefit managers pocket excessive profits. | high |
| 02 | If proven, the allegations expose a corporate culture that prioritized profit maximization for vendors over employee wellbeing, violating fundamental fiduciary obligations under federal law. | high |
| 03 | Wells Fargo had multiple alternatives available, including pass-through PBMs, specialty drug carve-outs, and NADAC-based pricing, all documented to save 20 to 40 percent on prescription spending. | medium |
| 04 | The case demonstrates that prescription drug overcharging is not an isolated incident but a systemic feature of lightly regulated PBM markets, with similar patterns documented across multiple employers and industries. | high |
| 05 | Without stronger transparency mandates, conflicts-of-interest prohibitions, and enforcement mechanisms, employees remain vulnerable to corporate arrangements that treat healthcare as a profit center rather than a worker benefit. | high |
| 06 | The lawsuit serves as a warning that even sophisticated employers with vast resources can fail their workers, underscoring the need for grassroots employee advocacy, legislative reform, and persistent litigation to demand accountability. | medium |
Timeline of Events
2017-2024
Wells Fargo allegedly allowed Express Scripts to overcharge employee health plan for prescription drugs
Multiple years
Wells Fargo paid over $25 million annually in administrative fees to Express Scripts
Multiple years
Employees contributed over $600 million per year to health plan, bearing 25% of inflated costs
Filed 2024
Class action lawsuit filed in U.S. District Court for the District of Minnesota alleging ERISA violations
Direct Quotes from the Legal Record
QUOTE 1
Extreme markup on MS drug fingolimod
allegations
“One can walk into a major retailer (Wegmans, Walmart, or Rite Aid) and fill a 90-unit prescription for roughly $648 to $900 without using insurance at all. Yet, the complaint alleges the Wells Fargo Plan was billed $9,994.37 for the exact same quantity.”
💡 This single example shows the plan paid more than 1,000 percent over retail for a common generic drug
QUOTE 2
Massive overcharge on teriflunomide
allegations
“The complaint claims the Plan paid $8,775.91 for 90 tablets, whereas pharmacies like Walmart or ShopRite could fill the same prescription for a fraction of that figure—often less than $80–$90 in cash prices.”
💡 Employees paid premiums and copays based on prices more than 100 times higher than necessary
QUOTE 3
Record-breaking markup on chemotherapy drug
allegations
“Imatinib (a chemotherapy drug used to treat certain leukemias): This drug’s markup soared as high as 4,700 percent above what the average pharmacy actually pays to acquire it wholesale.”
💡 Cancer patients faced financial devastation from markups that bore no relation to actual drug costs
QUOTE 4
Systematic pattern, not isolated incidents
allegations
“These are not isolated outliers! The filing systematically compares the Plan’s cost on dozens of generic drugs—especially ‘specialty’ generics that traditionally treat serious conditions, and finds triple-, quadruple-, even quadruple-digit markups above pharmacies’ real acquisition costs.”
💡 The lawsuit documents a pervasive scheme affecting many drugs and thousands of employees
QUOTE 5
Corporate duty violated
accountability
“The complaint alleges that this system was allowed to persist due to Wells Fargo’s failure to monitor, renegotiate, or even investigate alternative PBM arrangements, a clear violation of what ERISA calls the ‘duty of prudence.'”
💡 Federal law required Wells Fargo to actively protect employees, not passively accept overcharging
QUOTE 6
Prohibited transactions alleged
accountability
“The complaint also alleges that this arrangement may have constituted ‘prohibited transactions’ under ERISA, which bars fiduciaries from transferring plan assets for the benefit of parties with massively conflicting interests.”
💡 Wells Fargo may have committed federal violations by enriching Express Scripts at employees’ expense
QUOTE 7
Manipulated pricing benchmark
regulatory
“A common joke among insiders is that ‘AWP’ stands for ‘Ain’t What’s Paid.'”
💡 The pricing system Wells Fargo used is so unreliable that industry insiders mock it openly
QUOTE 8
Excessive administrative fees
profit
“The complaint alleges that Wells Fargo caused the Plan to pay over $25 million in administrative fees to Express Scripts in a single year, an average of $135.81 per participant. Comparable companies, also contracting with Express Scripts and employing tens of thousands of workers, allegedly paid far lower per-participant fees for effectively the same or better services.”
💡 Wells Fargo overpaid not just for drugs but also for basic administrative services
QUOTE 9
Employee financial burden quantified
workers
“Total participant contributions to the Wells Fargo & Company Health Plan have exceeded $600 million per year, on average, in recent years. The company enforces a consistent ratio of contributions, aiming to have employees pay about 25% of total plan costs while the employer pays the other 75%.”
💡 Every dollar of PBM overcharging cost employees 25 cents in higher premiums from their paychecks
QUOTE 10
Direct harm to sick employees
health
“People with multiple sclerosis, HIV, leukemia, or other chronic conditions face especially onerous bills when a PBM sets ‘specialty drug’ prices exponentially beyond typical retail. For some, it means skipping doses or cutting pills to manage costs—an obviously dangerous scenario.”
💡 Inflated prices forced critically ill workers to ration life-saving medications
QUOTE 11
Wealth disparity worsened
wealth
“If true, they expose a fundamental corporate ethos that places profit maximization for vendors (and potentially for Wells Fargo’s corporate bottom line) ahead of employee well-being, corporate social responsibility, and basic fiduciary obligations.”
💡 The lawsuit alleges Wells Fargo prioritized profits over the health and finances of its own workers
QUOTE 12
Systemic problem, not isolated failure
conclusion
“The complaint provides an unflattering blueprint of how large corporations, operating under the logics of neoliberal capitalism, may exploit regulatory loopholes, engage in opaque ‘spread pricing,’ and pass the true costs down to individuals in the form of bloated out-of-pocket expenses and inflated insurance premiums.”
💡 This case exposes a widespread corporate practice that harms workers across many employers
QUOTE 13
Better alternatives existed and were ignored
accountability
“The lawsuit’s underlying inference is that Wells Fargo’s leadership and relevant plan administrators were indifferent at best, or complicit at worst, allowing Express Scripts to funnel obscene margins off basic generics.”
💡 Wells Fargo executives had the power to stop the overcharging but chose not to act
QUOTE 14
Human toll on communities
workers
“Higher out-of-pocket costs can be financially ruinous, especially for employees on the lower rung of the salary scale. The harm radiates outward as families juggle budgets, forgoing other essentials like healthy food or childcare.”
💡 Prescription overcharges affected not just employees but their families and local economies
QUOTE 15
Fiduciary standard betrayed
accountability
“Under ERISA, fiduciaries are held to a ‘highest known to the law’ standard of care. Failing to monitor PBMs in the face of glaring red flags is not a small misstep; it is potentially betrayal of trust.”
💡 Wells Fargo violated the strongest legal duty that exists to protect employees
Frequently Asked Questions
What exactly did Wells Fargo do wrong according to the lawsuit?
The lawsuit alleges Wells Fargo violated federal law by allowing its pharmacy benefits manager, Express Scripts, to massively overcharge the employee health plan for prescription drugs. For example, the plan allegedly paid nearly $10,000 for a multiple sclerosis drug that costs $648 at Walmart. Wells Fargo failed to monitor these costs, negotiate fair prices, or consider cheaper alternatives, forcing employees to pay higher premiums and copays.
How much more did employees pay because of this alleged scheme?
The lawsuit documents markups ranging from hundreds to thousands of percent. One MS drug cost $9,994 through the plan versus $648 at retail. Another cost $8,775 versus $80-90 at Walmart. A chemotherapy drug was marked up 4,700 percent. Employees contributed over $600 million annually to the plan and paid 25 percent of all costs, so inflated prices directly increased their premium deductions and copays.
What is a pharmacy benefit manager and what did Express Scripts allegedly do?
A PBM negotiates drug prices and processes prescription claims for health plans. Express Scripts allegedly used spread pricing, charging Wells Fargo far more than it paid pharmacies and keeping the difference as profit. It forced employees to use its own pharmacy, Accredo, where it charged extreme markups. It also retained manufacturer rebates instead of passing savings to the plan, all while collecting over $25 million in administrative fees.
Why didn’t Wells Fargo stop this if the overcharging was so obvious?
The lawsuit alleges Wells Fargo breached its fiduciary duty under ERISA by failing to monitor, audit, or question Express Scripts. The bank never requested competitive bids, never considered pass-through PBMs that eliminate spread pricing, and never challenged inflated specialty drug designations. The complaint suggests corporate indifference or complicity, not vigilant oversight in employees’ best interests.
Who was harmed by these alleged practices?
Over 200,000 Wells Fargo employees and their families who participated in the health plan. Workers with chronic conditions like MS, cancer, and HIV faced especially high costs. All employees paid higher premiums through paycheck deductions. Lower-wage workers were hit hardest because the inflated costs were regressive, taking a larger share of income from those least able to afford it.
What could Wells Fargo have done differently?
The lawsuit identifies multiple alternatives Wells Fargo ignored: contract with pass-through PBMs that charge transparent fees and pass all rebates to the plan; demand pricing based on actual pharmacy acquisition costs instead of inflated benchmarks; carve out specialty drugs to specialized vendors; allow employees to use low-cost retail pharmacies; and regularly audit PBM claims to verify fair pricing.
Is this problem unique to Wells Fargo?
No. The lawsuit describes systematic features of the PBM industry, including opaque contracts, conflicts of interest, and regulatory loopholes that allow overcharging. The top three PBMs control over 75 percent of prescriptions. However, many employers have switched to transparent pass-through models, making Wells Fargo’s alleged failure to act despite its size and resources particularly notable.
What is ERISA and why does it matter here?
ERISA is the Employee Retirement Income Security Act, a federal law requiring employers who sponsor health plans to act as fiduciaries with the highest duty of care. Plan sponsors must manage benefits prudently and loyally in employees’ best interests. The lawsuit alleges Wells Fargo violated these duties by allowing Express Scripts to overcharge, waste plan assets, and harm participants.
How can employees find out if their own employer is overcharging them?
Employees can request plan documents including contracts with PBMs, ask HR how drug prices are benchmarked, compare specialty drug copays to cash prices at retail pharmacies, review Form 5500 filings for administrative fees, and ask whether the employer uses pass-through pricing or retains spread and rebates. If answers are evasive or costs seem inflated, consider consulting an ERISA attorney.
What can workers do to protect themselves from prescription overcharging?
Advocate within your company by asking HR and benefits administrators tough questions about PBM contracts and pricing transparency. Support legislative reforms requiring pass-through pricing and conflicts-of-interest disclosures. Compare cash prices at pharmacies like Costco or GoodRx before using insurance, as sometimes paying out of pocket costs less. Join or support employee advocacy groups pushing for better health benefits. If you suspect wrongdoing, consult an employment or ERISA attorney about potential legal action.
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
